C1 Esterase Inhibitor [Human] - Indication, Pharmacology, Warnings, and Precautions

Overview:

C1 esterase inhibitor (human) is a medicine formulated from human plasma. Plasma extracted from various donors’ blood prepares the C1 esterase inhibitor. The gathered plasma then undergoes specific processing, including pasteurization, purification, and lyophilization, to form a C1 esterase inhibitor concentrate. The drug governing body of the United States, the Food and Drug Administration (FDA), validated the prescription of C1 esterase inhibitor (human) for hereditary angioedema (an inborn medical condition where the person elicits puffiness and soreness in vital parts or organs). The C1 esterase inhibitor’s FDA authorization took effect in October 2008, and since then, it has been used extensively.

Drug Group:

Complement inhibitor is the drug class that accommodates the C1 esterase inhibitor (human). This category of medicines can regulate and modulate the body’s complement system, which is the constitutive element of the body’s defense mechanism. However, at times, the complement system may exhibit exaggerated functioning, eventually giving rise to ailments. Complement inhibitors are employed for such cases to limit and tie down the complement system, thereby alleviating the manifestations of the underlying disease condition.

Available Doses and Dosage Forms:

• Dosage Form: The powder form is the physical state of the C1 esterase inhibitor’s approved marketing formulation. However, powdered C1 esterase inhibitors are clubbed with a specific liquid for introduction into the body. The resulting solution is then employed for bodily administration through a shot.

• Available Dose: 500 IU (international units) is the C1 esterase dosage that is put up for sale.

For Patients:

What Is Hereditary Angioedema?

Hereditary angioedema, as the name implies, is a peculiar inherent and inborn condition where the affected person develops puffiness in organs like the skin, airway, or food tract. Airway tract puffiness can be alarming as it can impede the breathing passage, thereby compromising the respiratory gas flow. Hereditary angioedema is precipitated due to abnormalities in the genes. Altered genes can interrupt the normal bodily activities in which they are concerned. In hereditary angioedema, the genes that regulate C1 inhibitors get impaired, which results in abnormal activities in the immune system due to a deficit in C1 inhibitors.

The affected person starts eliciting obvious manifestations within 10 to 20 years. It often presents as frequent episodes, with each episode lasting for two to five days. Certain factors can potentiate the exacerbation of angioedema. Stress, infections, and injury are some of the known triggers concerning hereditary angioedema.

How Does C1 Esterase Inhibitor Work?

C1 esterase inhibitors check the activation of the C1 complex, an intrinsic complement component. Exaggerated activation of these complexes brings in the manifestations of hereditary angioedema. C1 esterase inhibitor, as the name says, interacts with the C1 complement molecules and establishes a bond with them. This impedes the C1 activation and thereby curtails unwanted complement activation. In addition, it compensates for the shortfall in the C1 inhibitor level in hereditary angioedema patients.

What Is the Dosage of C1 Esterase Inhibitor?

Younger patients and adult patients are advised of distinct C1 esterase inhibitor dosages.

1. For Pediatric Patients (Within the Age Range of Six to 11 Years):

• Recommended Dosage: 500 IU.

• Dosage Frequency: Every three or four days.

• The dosage can be upregulated slowly, considering the patient's tolerability. However, it should not exceed the adult dosage of 1000 IU.

2. For Patients Over 12 Years:

• Recommended Dosage: 1000 IU.

• Dosage Frequency: Once every three or four days.

• Considering the patient's tolerability, the dose can be titrated up to 2000 IU.

The C1 esterase inhibitor formulation is intended for intravenous (infusion directly into the vein) delivery. The drug infusion should be at the rate of one milliliter per minute.

How Effective Is C1 Esterase Inhibitor?

C1 esterase inhibitor has been proven fruitful and competent for the therapeutic management of hereditary angioedema. Therapeutic potentialities concerning C1 esterase inhibitors were undisputably revealed by studies based on which the FDA authorized its medical application in hereditary angioedema patients. C1 esterase inhibitors can successfully tackle the manifestation and swelling episodes associated with hereditary angioedema. In addition, it can offer prophylactic coverage to susceptible individuals. C1 esterase inhibitor’s ability to reduce the intensity, duration, and frequency of hereditary angioedema exacerbation episodes is exceptional. It also has a surprising safety profile, flags remarkable patient tolerability, and has the least possible side effects.

What Are the Things to Inform the Doctor Before Taking the Drug?

Therapy with a C1 esterase inhibitor mandates the need for methodical patient-doctor interaction.

• Prior exaggerated reactivity instances with C1 esterase inhibitors must be communicated with the doctor beforehand. Repeated subjectivity to an allergic component can bring about grave body responses. Unexplainable and astounding reactivity to any of the C1 esterase inhibitor injection formulation’s ingredients should also be addressed by the doctor prematurely to stamp out the risk of life-threatening events.

• Another core piece of information that one should provide to one's doctor is an up-to-date medical history. This should include details about the patient’s present medical conditions, such as heart disease, cured illnesses, and surgical history.

• The doctor should be informed about the patient’s drug history. This keeps the doctor mindful of conceivable drug-to-drug associations. Everything must be noted, including whether the medicine is over-the-counter, homeopathic, dietary supplements, herbal, or other alternatives.

• Let the doctors know the patient’s breastfeeding and pregnancy status. A baby in the womb may be influenced by certain maternal drugs, bringing out grave complications for the baby. Similarly, drug consumption by lactating mothers can also bring danger to the breastfed baby.

How Is C1 Esterase Inhibitor Administered?

Before administration, the injection formulation needs to be prepared. It is done by solvating the powdered drug form with a specific proportion of sterile water. One vial of C1 esterase inhibitors is made to liquefy in approximately five milliliters of sterile water. The dissolving is facilitated by gently rotating the vial. The dissolution results in the C1 esterase inhibitor drug formulation with a concentration of 100 IU per milliliter of the injection solution. Look over the solution for precipitate (particle clumps) or abnormal color, which denotes that the medicine is unsuitable for administration. Extract the injection formulation from the vial into a sterile syringe. Following this, the injection formulation has to be infused into a suitable blood vessel (vein) at one milliliter per minute. The reconstituted formulation is not intended for storage over three hours, and the leftover solution, if any, needs to be disposed of.

What Are the Side Effects of C1 Esterase Inhibitor?

Frequently encountered adverse effects of C1 esterase inhibitors include the following:

• Soreness at the injection point.

• Headache and faintness.

• Chills and sore throat.

• Unpleasant taste sensation.

• Teary eyes, sneezing, and runny nose.

• Tendency to throw up.

Besides the above-quoted side effects, it may also call forth certain rare adverse reactions that can challenge one's life. Some of them include:

• Heart racing.

• Short breath.

• Puffy extremities (legs and arms).

• Extensive skin rash.

• Weakness and loss of control over the body’s one side.

• Lips and skin flagging bluish discoloration.

• Troubled breathing.

These side effects warrant immediate medical attention and prompt intervention to safeguard their lives.

Dietary Considerations:

C1 esterase inhibitor therapy does not mandate any specific dietary considerations. However, foreseeing the patient's medical background, doctors might put forward certain guidelines concerning diet.

Missed Dose:

Patients must adhere to the customized dosage prescribed by their doctor. The drug dosage is spaced at an interval of three to four days. If the person fails to deliver the C1 esterase inhibitor dose on time and becomes conscious of it later, they can deliver once they gain knowledge of the overlooked dose. However, ensure a three- to four-day gap between subsequent doses. Sometimes, the person minds it during the next dose; then, it is advised to disregard and omit the overlooked dose.

Overdose:

Delivering more than the advised dosage of C1 esterase inhibitor can potentially precipitate overdose issues. C1 esterase inhibitor overdose warrants immediate medical care. Chest discomfort, collapse, shortness of breath, and faintness are grave signs of C1 esterase inhibitor overdose. In such instances, the poison control center or emergency services must be called for.

Storage:

Two to 25 degrees Celsius (36 to 77 degrees Fahrenheit) represents the safer temperature range under which the C1 esterase inhibitor injection formulation can be housed. However, it should never be subjected to freezing, as freezing the C1 esterase inhibitor vials can deteriorate their therapeutic properties. The vials encoding the medicine formulations are supplied with protective cartoon coverings, which should be retained until reconstitution.

For Doctors:

Indication:

• Hereditary angioedema patients (prophylactic treatment).

Dose:

The patient’s age is decisive in determining the dose of the C1 esterase inhibitor. However, slight modifications in the general dosing regimen will affect the patient’s response and tolerability.

• Six to 11 Years Age Group: Intravenous delivery of 500 IU of C1 esterase inhibitor is the preferred dosing regimen for patients under the six to 11 years age group. Subsequent doses have to be spaced at three to four days intervals.

• Over 12 Age Group: 1000 IU of C1 esterase inhibitor is the individual dosage advised for adult and adolescent patients. The dosage interval or frequency for this particular age group is advised to be the same as that of the pediatric patients (repeated every three to four days).

Dosing Considerations:

Though there is a specific dosage regimen, doctors can modify and titrate as per the individual patient’s response.

• Pediatric Patients Within Six to 11 Years of Age: The C1 esterase inhibitor dosage can be titrated gradually until the desired response is achieved. However, the dose should be within 1000 IU.

• Adult and Adolescent Patients (12 Years and Over): The dose titration can be made within the individual dosage limit of 2000 IU.

What Are the Pharmacological Aspects of C1 Esterase Inhibitor?

Mechanism of Action:

C1 esterase inhibitor is a natural component of the complement system. In addition to the complement system, it also holds an indispensable role in the bradykinin pathway and contact activation system. C1 esterase inhibitors, as the name says, check the complement component C1. The C1 triggers classical pathway initiation. Thus, the C1 esterase inhibitor tempered and altered the complement system.

C1 esterase inhibitors elicit their influence over the contact activation system by checking the activities of the coagulation factors XIIa and kallikreins (serine protease). These are the active elemental participants in the clotting cascade. By interrupting their activity, C1 esterase inhibitors succeed in checking inappropriate blood clot development within the blood vessels.

Furthermore, the C1 esterase inhibitor depletes the bradykinin production by interacting with certain enzymes responsible for bradykinin production. Bradykinin jacks up the permeability of blood vessels, allowing more fluid to permeate, eventually contributing to fluid gathering and augmenting swelling. C1 esterase inhibitor activity potentially depreciates bradykinin level, thus preventing angioedema attacks.

2. Pharmacodynamics:

The C1 esterase inhibitor’s plasma concentration flags definite escalation within 60 minutes following the drug shot. The C1 esterase inhibitor establishes a bond with the complement component C1, which hinders the activation of the complement pathway.

3. Pharmacokinetics:

Upon intravenous delivery of C1 esterase inhibitors, the drug is immediately available for action in the bloodstream. It is through the blood and the extravascular channels that the C1 esterase inhibitor gets distributed throughout. Proteolysis cleaves the C1 esterase inhibitor drug and releases amino acid molecules. Proteolytic degradation and renal excretion are the elimination pathways associated with C1 esterase inhibitors.

4. Toxicity:

There is not much information on the toxicity profile of the C1 esterase inhibitor. Subjection to more than the prescribed C1 esterase inhibitor drug dose can bring systemic toxicity issues. Following systemic overdose exposure, the person may elicit troubled breathing, chest heaviness, seizure, or even collapse. As the medicine is introduced through intravenous injection, there will be sudden inflation in the C1 esterase inhibitor’s plasma concentration following overdose introduction. Immediate medical intervention needs to be sought to deal with the C1 esterase inhibitor’s toxicity issues. The absence of studies concerning the C1 esterase inhibitor’s mutagenic, tumorigenic, and carcinogenic potentials makes it difficult to establish a conclusive toxicity profile.

5. Clinical Studies:

Double-blinded, randomized, placebo-controlled studies have elucidated the efficacy and safety aspects of the C1 esterase inhibitor. The subjects trialed with C1 esterase inhibitor evidenced an appreciable collapse in the angioedema attack frequency and intensity. Certain subjects even reported zero angioedema attack frequency during the study course. Attack duration also elicited considerable markdown. Thus, clinical studies have revealed the C1 esterase inhibitor’s potency in tackling the manifestations of hereditary angioedema, eventually appreciating the patient’s quality of life.

What Are the Contraindications of C1 Esterase Inhibitor?

• C1 esterase inhibitor allergy.

Warnings and Precautions:

• Being a blood-derived drug, C1 esterase inhibitor therapy poses the danger of transmissible infections. Hence, the patient should be well informed about the vulnerability of acquiring infectious pathogens from the medicinal formulation of the C1 esterase inhibitor.

• There are reports of thromboembolic events in conjunction with C1 esterase inhibitor therapy, particularly in hereditary angioedema patients. However, the regularity is estimated to be remarkable in individuals who flag known provocative factors for thromboembolic events.

• C1 esterase inhibitors are known to evoke hyperreactivity issues. During hypersensitivity, skin rash, labored and noisy breathing, collapsed blood pressure, and chest heaviness are encountered.

What Are the Drug Interactions of C1 Esterase Inhibitors?

No appreciable drug interactions were detailed for the C1 esterase inhibitor drug.

Specific Considerations:

• C1 Esterase Inhibitor Therapy During Pregnancy: The lack of relevant information concerning the C1 esterase inhibitor’s fetal toxicity potential curbs its application in expectant women. Therefore, pregnant women are generally advised to abstain from C1 esterase inhibitor therapy.

• C1 Esterase Inhibitor Therapy During Lactation: The influence C1 esterase inhibitor (human) could have on lactating women and breastfed babies is obscure. Therefore, C1 esterase inhibitor therapy is routinely not advised.

• C1 Esterase Inhibitor Therapy in the Pediatric Population: Though the C1 esterase inhibitor’s therapeutic potency has been substantiated in younger patients, its therapeutic applicability is limited to only those over six.

• C1 Esterase Inhibitor Therapy in the Geriatric Population: The therapeutic aspects of C1 esterase inhibitors in elderly patients are estimated to be on a par with adults.